MedTrace Logo

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2025-05-29

Study results available
· View outcomes & findings →

Summary

Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).

Conditions

Interventions

BIOLOGICAL

NGM120 30mg

NGM120 30mg Subcutaneous Injection

BIOLOGICAL

NGM120 100mg

NGM120 100mg Subcutaneous Injection

BIOLOGICAL

NGM120 30mg with Gemcitabine and Abraxane

NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

BIOLOGICAL

NGM120 100mg with Gemcitabine and Abraxane

NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

BIOLOGICAL

NGM120 100mg Q3W

NGM120 100mg Subcutaneous Injection every 3 weeks

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • NGM Study Director · NGM Biopharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-16
Primary Completion
2023-09-21
Completion
2024-01-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04068896 on ClinicalTrials.gov